详情页 - 首都医科大学附属北京同仁医院知识库

当前位置：首页 > 详情页

Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets

0| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]The Second Clinical School of Nanjing Medical University, Nanjing, China. [2]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [3]Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. [4]Department of Radiation Oncology, Jinling Hospital, Nanjing, China. [5]Department of Hematology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

出处：

DOI：

ISSN：

关键词： cancer associated fibroblast (CAF) hematologic malignancies crosstalk chemoresistance therapeutic target

摘要：

Hematologic malignancies comprise a diverse range of blood, bone marrow, and organ-related disorders that present significant challenges due to drug resistance, relapse, and treatment failure. Cancer-associated fibroblasts (CAFs) represent a critical component of the tumor microenvironment (TME) and have recently emerged as potential therapeutic targets. In this comprehensive review, we summarize the latest findings on the roles of CAFs in various hematologic malignancies, including acute leukemia, multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms, and lymphoma. We also explore their involvement in tumor progression, drug resistance, and the various signaling pathways implicated in their activation and function. While the underlying mechanisms and the existence of multiple CAF subtypes pose challenges, targeting CAFs and their associated pathways offers a promising avenue for the development of innovative treatments to improve patient outcomes in hematologic malignancies.Copyright © 2023 Ding, Shi, Hu, Tian, Sun, Wu and Zhang.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

最新[2023]版：

大类 | 3 区医学

小类 | 3 区肿瘤学

JCR分区：

出版当年[2021]版：

Q2 ONCOLOGY

最新[2023]版：

Q2 ONCOLOGY

影响因子： 3.5 最新[2023版] 4 最新五年平均 5.738 出版当年[2021版] 6.122 出版当年五年平均 6.244 出版前一年[2020版] 4.7 出版后一年[2022版]

第一作者：

第一作者机构： [1]The Second Clinical School of Nanjing Medical University, Nanjing, China.

共同第一作者：

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2 [2]First-in-human study of TQB3617, a BET inhibitor in patients with relapsed/refractory hematologic malignancies [3]Model-based Voriconazole Dose Optimization in Chinese Adult Patients With Hematologic Malignancies [4]Diabetic retinopathy: Neuron protection as a therapeutic target [5]Identification of mitochondrial RNA polymerase as a potential therapeutic target of osteosarcoma [6]Ferroptosis as a Potential Therapeutic Target for Reducing Inflammation and Corneal Scarring in Bacterial Keratitis [7]IL-10: A Key Regulator and potential therapeutic target in uveitis [8]The extracellular cyclophilin A-integrin β2 complex as a therapeutic target of viral pneumonia [9]SPAG5 as a novel biomarker and potential therapeutic target via regulating AKT pathway in multiple myeloma [10]Correction: Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.